Please disable your adblock and script blockers to view this page

Switch to Moderna booster after Pfizer shots better against omicron in 60+


Pfizer-BioNTech COVID-19
Moderna
National Centre for Infectious Diseases
Pfizer-BioNTech to Moderna
Young
Omicron
the Ars Orbital Transmission
CNMN Collection WIRED Media Group
Condé Nast


Beth Mole
Barnaby Young
Ars

No matching tags

No matching tags

No matching tags


Singapore

No matching tags

Positivity     34.00%   
   Negativity   66.00%
The New York Times
SOURCE: https://arstechnica.com/science/2022/05/older-adults-got-higher-omicron-protection-by-switching-from-pfizer-to-moderna/
Write a review: Ars Technica
Summary

At seven days after the booster, the heterologous-boosted participants had two-fold higher antibody levels than the homologous group and 60 percent higher levels at 28 days.Older heterologous-boosted participants also had higher levels of neutralizing antibodies against all of the SARS-CoV-2 variants tested—with the largest difference seen against omicron, which is notorious for thwarting vaccine-derived immune responses. At 28 days, the spread was 84 percent in the heterologous-boosted group to 73 percent in the homologous-boosted group.Overall, Young and co-authors concluded: "For the vulnerable older age group in particular, a heterologous booster COVID-19 vaccine regimen induces a higher anti-spike antibody titer and a stronger neutralizing antibody response against the highly infectious Omicron variant (~20 percent higher neutralization) than a homologous booster regimen."The trial is still ongoing, so the authors will continue to add participants and data.

As said here by Beth Mole